search

Active clinical trials for "Kidney Neoplasms"

Results 311-320 of 809

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or...

Kidney CancerMelanoma (Skin)

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells. PURPOSE: Phase II trial to study the effectiveness of high-dose interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer or melanoma.

Completed3 enrollment criteria

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Kidney Cancer

The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).

Completed9 enrollment criteria

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients with advanced bladder cancer.

Completed3 enrollment criteria

Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients...

Kidney Cancer

RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining interferon alfa and interleukin-2 with fluorouracil may kill any remaining tumor cells following surgery. It is not yet known whether combining interferon alfa and interleukin-2 with fluorouracil is more effective than observation after surgery for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combining interleukin-2, interferon alfa, and fluorouracil to that of observation alone in treating patients who have undergone surgery for kidney cancer and are at high risk of relapse.

Completed47 enrollment criteria

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.

Completed67 enrollment criteria

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic...

Kidney Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by donor peripheral stem cell transplantation in treating patients who have metastatic or unresectable kidney cancer.

Completed68 enrollment criteria

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable or metastatic kidney cancer.

Completed53 enrollment criteria

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

Childhood Soft Tissue SarcomaChildhood Liver Cancer3 more

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have refractory solid tumors.

Completed2 enrollment criteria

RPI.4610 in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.

Completed3 enrollment criteria

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter9 more

Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Completed30 enrollment criteria
1...313233...81

Need Help? Contact our team!


We'll reach out to this number within 24 hrs